Sepsis Biomarkers Comprehensive Study by Test (Blood tests, Confirmatory/Diagnostic Tests, Urine tests), Technology (Microbiology, Molecular Diagnostics, Polymerase Chain Reaction (PCR), DNA Microarrays, Syndromic Panel testing, Others), Microbes (Bacteria, Virus, Fungi, Parasites), Bio Marker (STREM-1, SuPAR, Pro-ADM, Presepsin) Players and Region - Global Market Outlook to 2027

Sepsis Biomarkers Market by XX Submarkets | Forecast Years 2023-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Sepsis Biomarkers Market Scope
The rising prevalence case of sepsis and Increasing awareness drives the market growth. The body's reaction to an infection results in sepsis, an uncommon systemic reaction. It's a medical emergency that could endanger life. Therefore, early detection of sepsis facilitates prompt treatment, enhances outcomes, and minimises needless antibiotic medication. Sepsis can be identified via biomarkers, allowing for early intervention that, while mostly supportive, can lower the chance of death. These biomarkers contribute to a decrease in the mortality rate brought on by severe sepsis. Since they may distinguish between systemic sepsis and a local infection as well as the presence or absence and severity of sepsis, biomarkers are frequently utilised in clinical practise to track the infectious process.

AttributesDetails
Study Period2017-2027
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledHOFFMANN-LA ROCHE LTD (Switzerland), Immunexoress, Inc. (United States), Becton Dickinson (United States), Danaher (United States), Luminex Corporation (United States), Thermo Fischer Scientific Inc. (United States), bioMerieux Inc. (France), T2 Biosystems (United States), Axis-Shield Diagnostics (United Kingdom), Abionic (Switzerland), Adrenomed (Germany), GenomeKey (United Kingdom), HelixBind (United States), Immunexpress (United States) and Momentum Bioscience (United Kingdom)
CAGR%


The market for the Sepsis Biomarker is highly competitive and dominated by few key player. The market has a vendor landscape that is extremely competitive. A number of businesses are also taking part in significant mergers and acquisitions as part of crucial plans to increase their market share globally. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Sepsis Biomarkers market throughout the predicted period.

HOFFMANN-LA ROCHE LTD (Switzerland), Immunexoress, Inc. (United States), Becton Dickinson (United States), Danaher (United States), Luminex Corporation (United States), Thermo Fischer Scientific Inc. (United States), bioMerieux Inc. (France), T2 Biosystems (United States), Axis-Shield Diagnostics (United Kingdom), Abionic (Switzerland), Adrenomed (Germany), GenomeKey (United Kingdom), HelixBind (United States), Immunexpress (United States) and Momentum Bioscience (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Sepset Biosciences (Canada), Spectral Medical (Canada), Abbott (United States), Bio-Rad Laboratories (United States) and Siemens Healthcare (Germany).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Sepsis Biomarkers market by Type and Region with country level break-up.

On the basis of geography, the market of Sepsis Biomarkers has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies
In March 2021, Roche acquired GenMark, a provider of multiplex molecular diagnostics to enhance Rocheís presence in the infectious disease diagnostics space and bring the company into the syndromic testing market. The Deal was valued at 1,832 Million USD
Recent development in electrochemical detection of sepsis in the year 2019 is the fabrication of needle-shaped microelectrodes which can detect the levels of IL-6 a sepsis biomarker


Influencing Trend:
Introduction of technologically advanced diagnostic solutions is the key trend driving the market growth

Market Growth Drivers:
The rising prevalence case of sepsis drives the market growth and Increasing diagnostic applications of biomarkers propels the market forward

Challenges:
Lack of skilled workforce worldwide restrict the market growth

Restraints:
Lack of standardization for the sepsis diagnosis coupled with lack of testing in emerging economies hampers the market growth

Opportunities:
Increasing awareness creates lucrative growth opportunities for the market and Increasing R&D investment in healthcare sector and government initiative creates tremendous growth opportunities for the market

Key Target Audience
New Entrants and Investors, Pharmaceutical Companies, Biotechnological Companies, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Test
  • Blood tests
  • Confirmatory/Diagnostic Tests
  • Urine tests

By Technology
  • Microbiology
  • Molecular Diagnostics
  • Polymerase Chain Reaction (PCR)
  • DNA Microarrays
  • Syndromic Panel testing
  • Others

By Microbes
  • Bacteria
  • Virus
  • Fungi
  • Parasites

By Bio Marker
  • STREM-1
  • SuPAR
  • Pro-ADM
  • Presepsin

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The rising prevalence case of sepsis drives the market growth
      • 3.2.2. Increasing diagnostic applications of biomarkers propels the market forward
    • 3.3. Market Challenges
      • 3.3.1. Lack of skilled workforce worldwide restrict the market growth
    • 3.4. Market Trends
      • 3.4.1. Introduction of technologically advanced diagnostic solutions is the key trend driving the market growth
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Sepsis Biomarkers, by Test, Technology , Microbes , Bio Marker and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Sepsis Biomarkers (Value)
      • 5.2.1. Global Sepsis Biomarkers by: Test (Value)
        • 5.2.1.1. Blood tests
        • 5.2.1.2. Confirmatory/Diagnostic Tests
        • 5.2.1.3. Urine tests
      • 5.2.2. Global Sepsis Biomarkers Region
        • 5.2.2.1. South America
          • 5.2.2.1.1. Brazil
          • 5.2.2.1.2. Argentina
          • 5.2.2.1.3. Rest of South America
        • 5.2.2.2. Asia Pacific
          • 5.2.2.2.1. China
          • 5.2.2.2.2. Japan
          • 5.2.2.2.3. India
          • 5.2.2.2.4. South Korea
          • 5.2.2.2.5. Australia
          • 5.2.2.2.6. Rest of Asia-Pacific
        • 5.2.2.3. Europe
          • 5.2.2.3.1. Germany
          • 5.2.2.3.2. France
          • 5.2.2.3.3. Italy
          • 5.2.2.3.4. United Kingdom
          • 5.2.2.3.5. Netherlands
          • 5.2.2.3.6. Rest of Europe
        • 5.2.2.4. MEA
          • 5.2.2.4.1. Middle East
          • 5.2.2.4.2. Africa
        • 5.2.2.5. North America
          • 5.2.2.5.1. United States
          • 5.2.2.5.2. Canada
          • 5.2.2.5.3. Mexico
    • 5.3. Global Sepsis Biomarkers (Price)
  • 6. Sepsis Biomarkers: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. HOFFMANN-LA ROCHE LTD (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Immunexoress, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Becton Dickinson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Danaher (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Luminex Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Thermo Fischer Scientific Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. BioMerieux Inc. (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. T2 Biosystems (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Axis-Shield Diagnostics (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Abionic (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Adrenomed (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. GenomeKey (United Kingdom)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. HelixBind (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Immunexpress (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Momentum Bioscience (United Kingdom)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Sepsis Biomarkers Sale, by Test, Technology , Microbes , Bio Marker and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Sepsis Biomarkers (Value)
      • 7.2.1. Global Sepsis Biomarkers by: Test (Value)
        • 7.2.1.1. Blood tests
        • 7.2.1.2. Confirmatory/Diagnostic Tests
        • 7.2.1.3. Urine tests
      • 7.2.2. Global Sepsis Biomarkers Region
        • 7.2.2.1. South America
          • 7.2.2.1.1. Brazil
          • 7.2.2.1.2. Argentina
          • 7.2.2.1.3. Rest of South America
        • 7.2.2.2. Asia Pacific
          • 7.2.2.2.1. China
          • 7.2.2.2.2. Japan
          • 7.2.2.2.3. India
          • 7.2.2.2.4. South Korea
          • 7.2.2.2.5. Australia
          • 7.2.2.2.6. Rest of Asia-Pacific
        • 7.2.2.3. Europe
          • 7.2.2.3.1. Germany
          • 7.2.2.3.2. France
          • 7.2.2.3.3. Italy
          • 7.2.2.3.4. United Kingdom
          • 7.2.2.3.5. Netherlands
          • 7.2.2.3.6. Rest of Europe
        • 7.2.2.4. MEA
          • 7.2.2.4.1. Middle East
          • 7.2.2.4.2. Africa
        • 7.2.2.5. North America
          • 7.2.2.5.1. United States
          • 7.2.2.5.2. Canada
          • 7.2.2.5.3. Mexico
    • 7.3. Global Sepsis Biomarkers (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Sepsis Biomarkers: by Test(USD Million)
  • Table 2. Sepsis Biomarkers Blood tests , by Region USD Million (2017-2022)
  • Table 3. Sepsis Biomarkers Confirmatory/Diagnostic Tests , by Region USD Million (2017-2022)
  • Table 4. Sepsis Biomarkers Urine tests , by Region USD Million (2017-2022)
  • Table 5. South America Sepsis Biomarkers, by Country USD Million (2017-2022)
  • Table 6. South America Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 7. South America Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 8. South America Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 9. South America Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 10. Brazil Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 11. Brazil Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 12. Brazil Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 13. Brazil Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 14. Argentina Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 15. Argentina Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 16. Argentina Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 17. Argentina Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 18. Rest of South America Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 19. Rest of South America Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 20. Rest of South America Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 21. Rest of South America Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 22. Asia Pacific Sepsis Biomarkers, by Country USD Million (2017-2022)
  • Table 23. Asia Pacific Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 24. Asia Pacific Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 25. Asia Pacific Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 26. Asia Pacific Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 27. China Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 28. China Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 29. China Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 30. China Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 31. Japan Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 32. Japan Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 33. Japan Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 34. Japan Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 35. India Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 36. India Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 37. India Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 38. India Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 39. South Korea Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 40. South Korea Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 41. South Korea Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 42. South Korea Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 43. Australia Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 44. Australia Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 45. Australia Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 46. Australia Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 47. Rest of Asia-Pacific Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 48. Rest of Asia-Pacific Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 49. Rest of Asia-Pacific Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 50. Rest of Asia-Pacific Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 51. Europe Sepsis Biomarkers, by Country USD Million (2017-2022)
  • Table 52. Europe Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 53. Europe Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 54. Europe Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 55. Europe Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 56. Germany Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 57. Germany Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 58. Germany Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 59. Germany Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 60. France Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 61. France Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 62. France Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 63. France Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 64. Italy Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 65. Italy Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 66. Italy Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 67. Italy Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 68. United Kingdom Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 69. United Kingdom Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 70. United Kingdom Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 71. United Kingdom Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 72. Netherlands Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 73. Netherlands Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 74. Netherlands Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 75. Netherlands Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 76. Rest of Europe Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 77. Rest of Europe Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 78. Rest of Europe Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 79. Rest of Europe Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 80. MEA Sepsis Biomarkers, by Country USD Million (2017-2022)
  • Table 81. MEA Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 82. MEA Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 83. MEA Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 84. MEA Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 85. Middle East Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 86. Middle East Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 87. Middle East Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 88. Middle East Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 89. Africa Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 90. Africa Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 91. Africa Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 92. Africa Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 93. North America Sepsis Biomarkers, by Country USD Million (2017-2022)
  • Table 94. North America Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 95. North America Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 96. North America Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 97. North America Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 98. United States Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 99. United States Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 100. United States Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 101. United States Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 102. Canada Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 103. Canada Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 104. Canada Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 105. Canada Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 106. Mexico Sepsis Biomarkers, by Test USD Million (2017-2022)
  • Table 107. Mexico Sepsis Biomarkers, by Technology USD Million (2017-2022)
  • Table 108. Mexico Sepsis Biomarkers, by Microbes USD Million (2017-2022)
  • Table 109. Mexico Sepsis Biomarkers, by Bio Marker USD Million (2017-2022)
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Company Basic Information, Sales Area and Its Competitors
  • Table 118. Company Basic Information, Sales Area and Its Competitors
  • Table 119. Company Basic Information, Sales Area and Its Competitors
  • Table 120. Company Basic Information, Sales Area and Its Competitors
  • Table 121. Company Basic Information, Sales Area and Its Competitors
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Sepsis Biomarkers: by Test(USD Million)
  • Table 126. Sepsis Biomarkers Blood tests , by Region USD Million (2022-2027)
  • Table 127. Sepsis Biomarkers Confirmatory/Diagnostic Tests , by Region USD Million (2022-2027)
  • Table 128. Sepsis Biomarkers Urine tests , by Region USD Million (2022-2027)
  • Table 129. South America Sepsis Biomarkers, by Country USD Million (2022-2027)
  • Table 130. South America Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 131. South America Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 132. South America Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 133. South America Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 134. Brazil Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 135. Brazil Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 136. Brazil Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 137. Brazil Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 138. Argentina Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 139. Argentina Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 140. Argentina Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 141. Argentina Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 142. Rest of South America Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 143. Rest of South America Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 144. Rest of South America Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 145. Rest of South America Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 146. Asia Pacific Sepsis Biomarkers, by Country USD Million (2022-2027)
  • Table 147. Asia Pacific Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 148. Asia Pacific Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 149. Asia Pacific Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 150. Asia Pacific Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 151. China Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 152. China Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 153. China Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 154. China Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 155. Japan Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 156. Japan Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 157. Japan Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 158. Japan Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 159. India Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 160. India Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 161. India Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 162. India Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 163. South Korea Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 164. South Korea Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 165. South Korea Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 166. South Korea Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 167. Australia Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 168. Australia Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 169. Australia Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 170. Australia Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 171. Rest of Asia-Pacific Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 172. Rest of Asia-Pacific Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 173. Rest of Asia-Pacific Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 174. Rest of Asia-Pacific Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 175. Europe Sepsis Biomarkers, by Country USD Million (2022-2027)
  • Table 176. Europe Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 177. Europe Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 178. Europe Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 179. Europe Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 180. Germany Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 181. Germany Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 182. Germany Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 183. Germany Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 184. France Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 185. France Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 186. France Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 187. France Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 188. Italy Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 189. Italy Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 190. Italy Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 191. Italy Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 192. United Kingdom Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 193. United Kingdom Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 194. United Kingdom Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 195. United Kingdom Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 196. Netherlands Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 197. Netherlands Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 198. Netherlands Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 199. Netherlands Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 200. Rest of Europe Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 201. Rest of Europe Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 202. Rest of Europe Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 203. Rest of Europe Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 204. MEA Sepsis Biomarkers, by Country USD Million (2022-2027)
  • Table 205. MEA Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 206. MEA Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 207. MEA Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 208. MEA Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 209. Middle East Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 210. Middle East Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 211. Middle East Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 212. Middle East Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 213. Africa Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 214. Africa Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 215. Africa Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 216. Africa Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 217. North America Sepsis Biomarkers, by Country USD Million (2022-2027)
  • Table 218. North America Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 219. North America Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 220. North America Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 221. North America Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 222. United States Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 223. United States Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 224. United States Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 225. United States Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 226. Canada Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 227. Canada Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 228. Canada Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 229. Canada Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 230. Mexico Sepsis Biomarkers, by Test USD Million (2022-2027)
  • Table 231. Mexico Sepsis Biomarkers, by Technology USD Million (2022-2027)
  • Table 232. Mexico Sepsis Biomarkers, by Microbes USD Million (2022-2027)
  • Table 233. Mexico Sepsis Biomarkers, by Bio Marker USD Million (2022-2027)
  • Table 234. Research Programs/Design for This Report
  • Table 235. Key Data Information from Secondary Sources
  • Table 236. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Sepsis Biomarkers: by Test USD Million (2017-2022)
  • Figure 5. South America Sepsis Biomarkers Share (%), by Country
  • Figure 6. Asia Pacific Sepsis Biomarkers Share (%), by Country
  • Figure 7. Europe Sepsis Biomarkers Share (%), by Country
  • Figure 8. MEA Sepsis Biomarkers Share (%), by Country
  • Figure 9. North America Sepsis Biomarkers Share (%), by Country
  • Figure 10. Global Sepsis Biomarkers share by Players 2022 (%)
  • Figure 11. Global Sepsis Biomarkers share by Players (Top 3) 2022(%)
  • Figure 12. Global Sepsis Biomarkers share by Players (Top 5) 2022(%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. HOFFMANN-LA ROCHE LTD (Switzerland) Revenue, Net Income and Gross profit
  • Figure 15. HOFFMANN-LA ROCHE LTD (Switzerland) Revenue: by Geography 2022
  • Figure 16. Immunexoress, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Immunexoress, Inc. (United States) Revenue: by Geography 2022
  • Figure 18. Becton Dickinson (United States) Revenue, Net Income and Gross profit
  • Figure 19. Becton Dickinson (United States) Revenue: by Geography 2022
  • Figure 20. Danaher (United States) Revenue, Net Income and Gross profit
  • Figure 21. Danaher (United States) Revenue: by Geography 2022
  • Figure 22. Luminex Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 23. Luminex Corporation (United States) Revenue: by Geography 2022
  • Figure 24. Thermo Fischer Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Thermo Fischer Scientific Inc. (United States) Revenue: by Geography 2022
  • Figure 26. BioMerieux Inc. (France) Revenue, Net Income and Gross profit
  • Figure 27. BioMerieux Inc. (France) Revenue: by Geography 2022
  • Figure 28. T2 Biosystems (United States) Revenue, Net Income and Gross profit
  • Figure 29. T2 Biosystems (United States) Revenue: by Geography 2022
  • Figure 30. Axis-Shield Diagnostics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Axis-Shield Diagnostics (United Kingdom) Revenue: by Geography 2022
  • Figure 32. Abionic (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Abionic (Switzerland) Revenue: by Geography 2022
  • Figure 34. Adrenomed (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Adrenomed (Germany) Revenue: by Geography 2022
  • Figure 36. GenomeKey (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. GenomeKey (United Kingdom) Revenue: by Geography 2022
  • Figure 38. HelixBind (United States) Revenue, Net Income and Gross profit
  • Figure 39. HelixBind (United States) Revenue: by Geography 2022
  • Figure 40. Immunexpress (United States) Revenue, Net Income and Gross profit
  • Figure 41. Immunexpress (United States) Revenue: by Geography 2022
  • Figure 42. Momentum Bioscience (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 43. Momentum Bioscience (United Kingdom) Revenue: by Geography 2022
  • Figure 44. Global Sepsis Biomarkers: by Test USD Million (2022-2027)
  • Figure 45. South America Sepsis Biomarkers Share (%), by Country
  • Figure 46. Asia Pacific Sepsis Biomarkers Share (%), by Country
  • Figure 47. Europe Sepsis Biomarkers Share (%), by Country
  • Figure 48. MEA Sepsis Biomarkers Share (%), by Country
  • Figure 49. North America Sepsis Biomarkers Share (%), by Country
List of companies from research coverage that are profiled in the study
  • HOFFMANN-LA ROCHE LTD (Switzerland)
  • Immunexoress, Inc. (United States)
  • Becton Dickinson (United States)
  • Danaher (United States)
  • Luminex Corporation (United States)
  • Thermo Fischer Scientific Inc. (United States)
  • bioMerieux Inc. (France)
  • T2 Biosystems (United States)
  • Axis-Shield Diagnostics (United Kingdom)
  • Abionic (Switzerland)
  • Adrenomed (Germany)
  • GenomeKey (United Kingdom)
  • HelixBind (United States)
  • Immunexpress (United States)
  • Momentum Bioscience (United Kingdom)
Additional players considered in the study are as follows:
Sepset Biosciences (Canada) , Spectral Medical (Canada) , Abbott (United States) , Bio-Rad Laboratories (United States) , Siemens Healthcare (Germany)
Select User Access Type

Key Highlights of Report


Sep 2022 206 Pages 59 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Sepsis Biomarkers Market are by end use application [].
The Sepsis Biomarkers Market is gaining popularity and expected to see strong valuation by 2027.
  • The rising prevalence case of sepsis drives the market growth
  • Increasing diagnostic applications of biomarkers propels the market forward

Know More About Global Sepsis Biomarkers Market Report?